Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 31st Preview)
-
In vivo CAR T dealmaking accelerates
Johnson & Johnson moved deeper into in vivo CAR T by paying $785 million upfront to collaborate with Sail Biomedicines and taking an option to acquire the company for $2.58 billion. The deal pairs J&J’s immune-mediated disease program with Sail’s delivery platform, which uses circular RNA to support durable CD19 CAR expression in T cells. Sail’s lead program, SAIL-0839, is designed to target CD4 and CD8 T cells for autoimmune indications. J&J will invest $465 million via an equity component and make $140 million in milestone payments tied to development goals, with the acquisition option providing additional upside if the platform scales. The transaction underscores how big pharma is treating in vivo CAR T as a portfolio-building opportunity, following similar bets across the sector that aim to expand access to CAR T by reducing manufacturing complexity versus ex vivo approaches.
-
Regeneron–Sanofi Dupixent growth and partnership expansion talks
Regeneron reported another strong quarter for Dupixent, driven by label expansions and continued demand across approved indications, with worldwide sales reaching $6 billion for the first time in the second quarter. The rebound follows a period of slower growth and fueled group-wide revenue gains. Regeneron also said it repaid its Sanofi development balance of $3.1 billion, reducing its reported collaboration revenue going forward. Separately, the companies’ CEOs indicated they are in early stages of discussions about expanding their Dupixent collaboration into additional assets that could fit the IL-4/13 portfolio. The updates highlight both near-term commercialization momentum and longer-term business strategy around how to reinvest in follow-on indications as growth faces stronger annual comparisons in the second half of 2026.
-
Alnylam ATTR franchise takes earnings-driven hit
Alnylam’s stock slid sharply after the company lowered full-year guidance for its transthyretin amyloidosis franchise, citing normalized Amvuttra demand after a pent-up launch surge. The update came as investors focused on whether Amvuttra could sustain growth after earlier expectations. Amvuttra generated $1.01 billion in the quarter, missing analysts’ estimates by about 4%, while Alnylam said second-line growth has normalized. Management emphasized that first-line starts remain the focus and that physician preference and adherence metrics are holding up in the U.S. The guidance cut raises questions about the trajectory for the broader TTR cardiomyopathy market amid intensifying competition, including other ATTR cardiomyopathy therapies and upcoming franchise pressure from pipeline and performance data.
-
Novo Nordisk ziltivekimab fails in late-stage heart-inflammation bet
Novo Nordisk disclosed that ziltivekimab failed in a key Phase 3 cardiovascular outcomes study, dealing a setback to an anti-inflammatory approach aimed at linking cardiovascular inflammation to heart disease. The company described opportunities to salvage the wider program through ongoing trials in separate studies. The failure is being treated by investors as more than a single-drug disappointment, because inflammation-directed cardiovascular strategies have been under scrutiny across the sector after recent trial disappointments. Novo Nordisk’s update also fueled broader sentiment shifts in cardiovascular biotech names. Novo said the program’s Artemis and Hermes trials remain active, with management pointing to pathways to reassess the molecule’s potential if other studies demonstrate differential effects by patient population or trial design.
-
FDA advisory panel backs Replimune’s RP-1 for melanoma
Replimune’s RP-1 won support from an FDA advisory committee after the therapy had previously been rejected twice, with panelists concluding the efficacy evidence was evaluable and clinically meaningful. The vote heightens the chance the FDA will approve RP-1 for unresectable metastatic cutaneous melanoma in patients whose disease progressed on or after anti–PD-1 therapy. The agency is scheduled to decide by Aug. 2. Replimune is seeking to position RP-1 in combination with Opdivo to address a population with limited response rates, while FDA career scientists previously criticized how responses and survival analyses were interpreted in the single-arm design. The advisory recommendation comes after a contentious resubmission in which Replimune defended the trial design and the survival comparisons used to support clinical benefit, setting up a decisive regulatory outcome for the program.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.